The recent advances in classic BCR-ABL-negative myeloproliferative disorders.
Tefferi
Ayalew
A
Professor of Medicine, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
D018450:Disease Progression; D016044:Fusion Proteins, bcr-abl; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D011788:Quality of Life; D016896:Treatment Outcome
D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2